Monday, November 18, 2024
- 10:30AM-12:30PM
-
Abstract Number: 2294
Pharmacodynamic Effects of Nipocalimab on Disease Biomarkers in Patients with Moderate-to-Severe Active Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2 Study
Sjögren's Syndrome – Basic & Clinical Science Poster II- 10:30AM-12:30PM
-
Abstract Number: 2054
Phenotypical Differences in VEXAS Syndrome, Where Are We a Year Later? Results from a National Cohort Focused on Rheumatological Patients
Miscellaneous Rheumatic & Inflammatory Diseases Poster III- 10:30AM-12:30PM
-
Abstract Number: 2109
Pincer Grip and Metacarpophalangeal Patterns Emerge as New Phenotypes of Hand Osteoarthritis Using a Data Driven Approach: Data from the Osteoarthritis Initiative
Osteoarthritis – Clinical Poster II- 10:30AM-12:30PM
-
Abstract Number: 2068
Poloxamers 188 & 182 Are Effective in Repairing the Membrane Resealing Defect in Myositis
Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III- 10:30AM-12:30PM
-
Abstract Number: 2504
Polyarteritis Nodosa Associated with VEXAS Syndrome and Chronic Myelomonocytic Leukemia Compared with Primary Forms: A Case-Control Study
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III- 10:30AM-12:30PM
-
Abstract Number: 2457
Polypharmacy, Drug-drug Interactions, and Adverse Drug Reactions Among Systemic Sclerosis Patients: A Cross-sectional Risk Factor Study
Systemic Sclerosis & Related Disorders – Clinical Poster III- 10:30AM-12:30PM
-
Abstract Number: 2130
Post-fracture Survival for Rheumatoid Arthritis Patients Is Not Improving
Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster- 10:30AM-12:30PM
-
Abstract Number: 1976
Post-Hoc Analysis of Clinically Relevant Anti-Vaccine Antibodies in Participants with Rheumatoid Arthritis Treated with Nipocalimab
Immunological Complications of Medical Therapy Poster- 10:30AM-12:30PM
-
Abstract Number: 1839
PPP2R3C Overexpression Suppresses TCR -mediated CD4+ T Cell Abnormal Activation in Systemic Lupus Erythematosus via JNK and AKT-mTOR Pathways
T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster- 10:30AM-12:30PM
-
Abstract Number: 1841
Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases
T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster- 10:30AM-12:30PM
-
Abstract Number: 2400
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts
SLE – Diagnosis, Manifestations, & Outcomes Poster III- 10:30AM-12:30PM
-
Abstract Number: 2020
Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase
Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III- 10:30AM-12:30PM
-
Abstract Number: 2349
Predictive Potential of Serum Metabolites Associated with Treatment Response to Interleukin -17 Inhibitors in Patients with PsA